Tag Archives: mesothelioma treatment

Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes

mesothelioma treatment delays

Mesothelioma treatment delays that happened because of the COVID-19 pandemic will probably impact survival rates for some patients.  A new study of Canadian lung cancer patients found that more than half of them stopped or delayed treatment because of concerns about the virus this spring. Pleural mesothelioma is a lung-related cancer. Like lung cancer patients, mesothelioma patients face a higher risk of virus-related complications because they already have breathing problems.  But mesothelioma is also a fast-growing cancer. Most patients get several kinds of treatment at the same time. Mesothelioma treatment delays may give tumors a chance to grow unchecked.  A Catch-22 for Mesothelioma Patients Mesothelioma patients and others with lung diseases have had to make some difficult decisions because of … Continue reading Pandemic-Related Mesothelioma Treatment Delays Could Impact Outcomes »

Isolated Thoracic Perfusion for Mesothelioma Symptom Relief

isolated thoracic perfusion for mesothelioma

A new study suggests that a treatment called isolated thoracic perfusion could help alleviate some of the worst symptoms of malignant pleural mesothelioma. Isolated thoracic perfusion is a method for circulating medicine in just one area of the body. When doctors circulated chemotherapy drugs in the chests of people with pleural mesothelioma, their symptoms went away for several months.  Now, the team says it is time to test the technique in a bigger pool of mesothelioma patients.  The Theory Behind ITP Pleural mesothelioma is a membrane cancer that occurs in the chest. Chemotherapy drugs like Alimta can be powerful weapons against pleural mesothelioma. But they can also damage healthy tissues.  When healthy tissues are damaged by chemotherapy, mesothelioma patients can … Continue reading Isolated Thoracic Perfusion for Mesothelioma Symptom Relief »

Trimodal Mesothelioma Treatment May Not Be Worth the Risk

Japanese researchers say trimodality treatment for mesothelioma that includes chemotherapy, extrapleural pneumonectomy (EPP), and post-surgical radiation may not be beneficial enough to justify the risk. Pleural mesothelioma is one of the most difficult cancers to treat because it grows quickly and is resistant to most conventional therapies. Most mesothelioma patients have to have a combination of treatments. The question for researchers is, which treatment combination will provide the best mesothelioma survival outcomes. Trimodality Treatment for Mesothelioma In the newest study on trimodality treatment for mesothelioma, the Japanese team enrolled newly-diagnosed pleural mesothelioma patients who had not yet had any treatment. Study participants were given a chemotherapy combination of pemetrexed and cisplatin to shrink their mesothelioma tumors. This was followed by EPP … Continue reading Trimodal Mesothelioma Treatment May Not Be Worth the Risk »

Surgery Remains “Cornerstone” of Mesothelioma Treatment

A major new study of more than 14,000 mesothelioma patients diagnosed between 1973 and 2009 finds that surgery appears to have a greater impact on survival than any other form of mesothelioma treatment. Researchers with Mount Sinai Medical Center, North Shore/Long Island Jewish Health System, and Hofstra School of Medicine in New York analyzed data from SEER (Surveillance, Epidemiology, and End Results), a large national database of cancer patients. Only patients with confirmed malignant pleural mesothelioma were included in the study. The researchers divided 14,228 mesothelioma cases by age, sex race, diagnosis year, stage, cancer-directed surgery, radiation and other factors to determine which ones appear to have the most influence on mesothelioma survival. When compared to having no treatment, cancer-directed … Continue reading Surgery Remains “Cornerstone” of Mesothelioma Treatment »

Orphan Drug Approval Could Mean New Mesothelioma Treatment Option

A drug designed to fight cancer by destroying the stem cells that give rise to new cancer cells has been granted orphan drug status for the treatment of malignant mesothelioma. The designation paves the way for mesothelioma patients, who often have few treatment options, to get access to VS-5584 earlier than it would otherwise be available. VS-5584 is a powerful inhibitor of a signaling pathway that regulates cancer progression and the survival of cancer stem cells. According to Verastem, the Boston-based maker of VS-5584, the drug has already received a similar designation for mesothelioma in Europe. “This is an important regulatory milestone for Verastem and… will facilitate our global development of VS-5584 to help improve the available treatment options for patients suffering … Continue reading Orphan Drug Approval Could Mean New Mesothelioma Treatment Option »

NIH Grant May Help Validate Light-Based Therapy for Mesothelioma

University of Pennsylvania researchers studying a promising mesothelioma treatment that kills cancer cells with light will get the opportunity to take their research to the next level thanks to a significant new grant. Penn’s Perelman School of Medicine has received $8 million from the National Cancer Institute to delve deeper into the effects of photodynamic therapy (PDT) in patients with malignant pleural mesothelioma. The team has been researching and using the treatment in patients for several years, but the grant will allow them to conduct a larger clinical trial to further validate their good results. “This trial represents a major step in understanding the combination of treatment modalities that will offer patients the best hope for survival and extended remission,” … Continue reading NIH Grant May Help Validate Light-Based Therapy for Mesothelioma »

New Mesothelioma Treatment Boosts Chemotherapy Response

An important new study from one of the country’s top mesothelioma research labs has found a way to significantly boost the impact of chemotherapy on mesothelioma patients who are not eligible for surgery. Dr. Raffit Hassan and his colleagues at the National Cancer Institute have been focusing their efforts on an immunotoxin – a potent toxin inked to an antibody – to selectively target mesothelioma cells. The immunotoxin, called SS1P, is designed to target a protein called mesothelin, which is overexpressed in mesothelioma cells. While previous studies have shown some promise in SS1P treatment by itself, especially when the immune system is suppressed, the newest study tests the value of SS1P in combination with the most popular mesothelioma chemotherapy drugs, … Continue reading New Mesothelioma Treatment Boosts Chemotherapy Response »

Human Trials Planned for Promising New Mesothelioma Drug

Researcher

The Australian Asbestos Diseases Research Institute says it is ready to begin human trials on what its lead researcher calls the first significant advance in mesothelioma treatment in a decade. More than three years in development, TargomiRs utilizes a unique ‘minicell’ delivery system to insert a synthetic form of missing genetic material into mesothelioma cells. Like a number of other types of cancer, mesothelioma cells are missing a family of microRNAs critical to regulating the cellular life cycle. TargomiRs restores these microRNAs. In mice with human-derived mesothelioma, TargomiRs produced a “remarkable inhibition of tumour growth”, according to the Asbestos Diseases Research Institute. “The last significant development in the treatment of mesothelioma occurred ten years ago,” ADRI director Nico van Zandwijk … Continue reading Human Trials Planned for Promising New Mesothelioma Drug »

Monoclonal Antibody a ‘Novel Treatment’ for Mesothelioma?

A drug currently used to treat colorectal cancer and some types of head and neck cancer may also offer a new way to combat mesothelioma. Malignant pleural mesothelioma is an asbestos-linked cancer that spreads across the mesothelial tissue surrounding the lungs. The disease is highly resistant to most conventional therapies and is often fatal within a year of diagnosis.  As the number of mesothelioma cases continues to increase in many developing counties, scientists around the world are studying mesothelioma cells for clues that could help them develop more effective treatments. One clue is the overexpression of epidermal growth factor receptor (EGFR). EGFR is overexpressed by mesothelioma cells and several other types of cancer cells. The monoclonal antibody cetuximab, which is derived … Continue reading Monoclonal Antibody a ‘Novel Treatment’ for Mesothelioma? »

Perifosine May Offer New Mesothelioma Treatment

The makers of the anti-cancer drug perifosine say new research suggests the drug may offer a new way to fight malignant mesothelioma. The research article entitled “Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma” was recently published in the peer-reviewed online medical journal Plos One. The announcement has been picked up by other news outlets because of the rarity of new treatments for mesothelioma, the asbestos-linked cancer that is diagnosed in about 2,500 Americans every year. In the new study, perifosine was tested on human mesothelial cells and a variety of mesothelioma cell lines to demonstrate its effectiveness alone or in combination with other mesothelioma treatments. When given at a high enough dose, perifosine interfered … Continue reading Perifosine May Offer New Mesothelioma Treatment »